Study guide
11.1 Respiratory Tract Infections: Otitis, Sinusitis, Pharyngitis, CAP & HAP
PEBC Pharmacist Qualifying Examination Part I MCQ
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Canadian Pharmacy Regulatory Framework & Federal Legislation
1.1 Food and Drugs Act, Regulations, and Health Canada Oversight 1.2 Controlled Drugs and Substances Act (CDSA) & Controlled Substances Regulations (CSR) 1.3 NAPRA Drug Scheduling Framework & National Model Standards of Practice
2 Chapter 2: Ethics, Scope of Practice & Safety Culture
2.1 Professional Ethics, Fiduciary Duty & Health Information Privacy 2.2 Expanded Scope of Practice: Minor Ailments Prescribing, Renewals & Injections 2.3 Equity, Diversity, Inclusion, Cultural Safety & Continuous Quality Improvement
3 Chapter 3: Pharmaceutical Calculations & Posology
3.1 Concentrations, Dilutions, Alligations & Reconstitution 3.2 Dosing by Weight/BSA, Days Supply & Pediatric/Geriatric Dose Adjustments 3.3 IV Infusion Rates, Drop Factors, Osmolarity & Creatinine Clearance (Cockcroft-Gault)
4 Chapter 4: Compounding, Dispensing & Product Integrity
4.1 Non-Sterile Compounding & Beyond-Use Dating (NAPRA Standards) 4.2 Sterile Preparations & Hazardous Drug Handling (NAPRA / NIOSH Principles) 4.3 Prescription Verification, Auxiliary Labeling, Cold Chain & Medication Incident Prevention (ISMP Canada) 4.4 Dispensing Operations: Interchangeability, Adjudication, Compliance Packaging, Release & Inventory Control
5 Chapter 5: Clinical Pharmacology & Pharmacokinetics
5.1 Pharmacokinetic Principles: Clearance, Volume of Distribution, Half-life & Steady State 5.2 Cytochrome P450 Enzymes, Transporters & Significant Drug-Drug Interactions 5.3 Therapeutic Drug Monitoring (TDM), Narrow Therapeutic Index Drugs & Toxicities
6 Chapter 6: Evidence-Based Medicine & Literature Appraisal
6.1 Study Designs, Bias & Levels of Evidence in Clinical Research 6.2 Biostatistics: ARR, RRR, NNT, NNH, Confidence Intervals & P-values 6.3 Applying Canadian Practice Guidelines to Clinical Decision-Making 6.4 Drug Information Practice, Diagnostic Test Accuracy & Pharmacoeconomics
7 Chapter 7: Cardiovascular Pharmacotherapy: Hypertension, Dyslipidemia & CAD
7.1 Hypertension Management (Hypertension Canada Guidelines, Targets & Regimens) 7.2 Dyslipidemia & Atherosclerotic Cardiovascular Disease (CCS Guidelines & Statin Therapy) 7.3 Ischemic Heart Disease & Acute Coronary Syndromes (Antiplatelet & Antianginal Therapy)
8 Chapter 8: Cardiovascular Pharmacotherapy: Heart Failure, Arrhythmias & Anticoagulation
8.1 Heart Failure with Reduced & Preserved Ejection Fraction (GDMT & Monitoring) 8.2 Atrial Fibrillation, Arrhythmias & Rate vs. Rhythm Control 8.3 Venous Thromboembolism & Anticoagulation Therapy (DOACs, Warfarin & Thrombosis Canada)
9 Chapter 9: Endocrine & Metabolic Disorders
9.1 Type 2 Diabetes: Glycemic Targets, Non-Insulin Pharmacotherapy (Diabetes Canada) 9.2 Insulin Regimens, Type 1 Diabetes, Hypoglycemia & Diabetic Emergencies (DKA/HHS) 9.3 Thyroid Disorders & Osteoporosis (Diagnostic Parameters & Therapeutic Management)
10 Chapter 10: Respiratory & Gastrointestinal Disorders
10.1 Asthma Management & Exacerbations (CTS Guidelines, Relievers & Controllers) 10.2 Chronic Obstructive Pulmonary Disease (COPD) & Inhaler Delivery Systems 10.3 Gastroesophageal Reflux Disease (GERD), Peptic Ulcer Disease & GI Bleeding 10.4 Lower GI & Liver Disorders: Constipation, Diarrhea, IBS, IBD & Cirrhosis
11 Chapter 11: Infectious Diseases & Antimicrobial Stewardship
11.1 Respiratory Tract Infections: Otitis, Sinusitis, Pharyngitis, CAP & HAP 11.2 Urinary Tract, Skin/Soft Tissue & Sexually Transmitted Infections 11.3 Systemic Infections, Clostridioides difficile & Antimicrobial Stewardship Principles 11.4 HIV Prevention & Treatment, Viral Hepatitis, Tuberculosis & Fungal Infections
12 Chapter 12: Central Nervous System & Mental Health
12.1 Major Depressive Disorder & Anxiety Disorders (First-Line Agents & Safety) 12.2 Bipolar Disorder, Schizophrenia & Psychopharmacology Monitoring 12.3 Epilepsy, Seizure Types, Antiseizure Medications & Neuropathic Pain 12.4 Dementia, Parkinson Disease, Migraine, Insomnia & Restless Legs Syndrome
13 Chapter 13: Special Populations, Pain Management & Substance Use
13.1 Acute & Chronic Pain Management: Multimodal Analgesia & Opioid Stewardship 13.2 Substance Use Disorders: Opioid Agonist Therapy, Harm Reduction & Alcohol Withdrawal 13.3 Special Populations: Pharmacotherapy in Pregnancy, Lactation & Geriatrics (Deprescribing / Beers) 13.4 Palliative Care & Pediatric Pharmacotherapy
14 Chapter 14: Renal, Rheumatologic, Hematologic & Oncology Supportive Care
14.1 Chronic Kidney Disease, Acute Kidney Injury & Electrolyte Disorders 14.2 Osteoarthritis, Rheumatoid Arthritis & Gout 14.3 Anemias & Oncology Supportive Care
15 Chapter 15: Minor Ailments, Dermatology and Women's & Men's Health
15.1 Minor Ailments I: Allergic Rhinitis, Colds & Influenza, Eye and Ear Conditions 15.2 Minor Ailments II: Acne, Dermatitis, Psoriasis, Lice, Scabies & Sun Protection 15.3 Women's & Men's Health: Contraception, Emergency Contraception, Menopause, BPH, ED & Overactive Bladder
16 Chapter 16: Immunization & Health Promotion
16.1 Immunization Practice: NACI Recommendations, Administration, Cold Chain & Adverse Events 16.2 Health Promotion: Smoking Cessation, Weight Management, Screening & Social Determinants of Health
17 Chapter 17: Patient Care Process, Communication & Stewardship
17.1 The Patient Care Process: Assessment, Care Planning & Patient Interviewing 17.2 Patient Education, Device Counselling, Health Literacy & Overcoming Barriers 17.3 Interprofessional Collaboration, Pharmacy Workflow, Team Delegation & Drug Shortage Stewardship
11.1 Respiratory Tract Infections: Otitis, Sinusitis, Pharyngitis, CAP & HAP
Key Takeaways Explain This Topic AI
Under the Canadian Paediatric Society statement, mildly ill children 6 months or older with AOM may be observed for 24 to 48 hours, while a bulging eardrum with fever of 39°C or more, severe otalgia, 48 hours of illness, or perforation calls for antibiotics.
AOM first-line is amoxicillin 75 to 90 mg/kg/day BID (10 days under age 2); after failure, CPS uses 7:1 amoxicillin-clavulanate 45 to 60 mg/kg/day TID, as no 14:1 product exists in Canada.
Acute bacterial rhinosinusitis (ABRS) is distinguished from viral rhinosinusitis by persistent symptoms without improvement for ≥ 10 days, severe onset with high fever (≥ 39°C) and purulence for ≥ 3–4 consecutive days, or 'double sickening'; first-line empiric treatment is amoxicillin or amoxicillin-clavulanate.
Group A Streptococcal (GAS) pharyngitis should be confirmed microbiologically via Rapid Antigen Detection Testing (RADT) or throat culture using Centor/McIsaac criteria before starting penicillin V (300–600 mg PO BID–TID for 10 days) or amoxicillin, with the full 10-day duration required to prevent acute rheumatic fever (ARF).
Community-acquired pneumonia (CAP) risk stratification utilizes CURB-65 criteria; outpatients without comorbidities receive amoxicillin (1 g PO TID) or doxycycline (100 mg PO BID), whereas patients with comorbidities (COPD, diabetes, CKD, heart failure) require beta-lactam combination therapy (amoxicillin-clavulanate or cefuroxime plus a macrolide or doxycycline) or respiratory fluoroquinolone monotherapy (levofloxacin, moxifloxacin).
Last updated: October 2026
Respiratory Tract Infections: Otitis, Sinusitis, Pharyngitis, CAP & HAP
Respiratory tract infections represent the most frequent indication for outpatient antimicrobial prescriptions in Canada. However, because viral etiologies predominate in upper respiratory presentations, inappropriate antimicrobial utilization drives significant community-wide selective pressure and adverse drug events. Pharmacists play a pivotal clinical role in evaluating symptom severity, distinguishing viral illnesses from invasive bacterial infections, calculating precise weight-based posology, and applying validated risk-stratification scoring systems to optimize patient outcomes and antimicrobial stewardship.
Acute Otitis Media (AOM): Triage, Dosing & Watchful Waiting
Acute otitis media (AOM) is defined by rapid onset of middle ear inflammation accompanied by middle ear effusion (MEE), evidenced by tympanic membrane (TM) bulging, erythema, cloudiness, or otorrhea. The primary bacterial pathogens responsible for AOM in Canadian pediatric populations include:
Streptococcus pneumoniae (35%–40%): Associated with severe pain, high fever, and suppurative complications.
Haemophilus influenzae (non-typeable) (30%–35%): Frequently isolated in otitis-conjunctivitis syndrome; approximately 30%–45% of Canadian strains produce beta-lactamase.
Moraxella catarrhalis (10%–15%): Greater than 90% produce beta-lactamase.
Respiratory viruses (RSV, rhinovirus, influenza): Often co-present, causing mucosal swelling and Eustachian tube dysfunction.
Watchful Waiting Protocol vs. Immediate Antimicrobial Therapy
Because up to 80% of uncomplicated AOM cases resolve spontaneously within 2 to 7 days without antibacterial therapy, clinical practice guidelines recommend a structured watchful waiting (delayed prescription) approach for select low-risk pediatric patients.
- Clinical Criterion Watchful Waiting (CPS: Observe 24–48 Hours) Immediate Antibiotic Therapy
- Age Threshold Age ≥ 6 months Age < 6 months (always treat immediately)
- Symptom Severity Mild otalgia, fever < 39°C Moderate-to-severe otalgia, fever ≥ 39°C, or toxic appearance
Duration / Laterality Ill for less than 48 hours Significantly ill for 48 hours or more (the AAP also treats bilateral AOM under 2 years immediately)
Tympanic Membrane Intact TM with mild-to-moderate bulging Perforated TM with acute purulent otorrhea
Follow-up Reliability Caregiver able to monitor and return, or fill a delayed prescription, if no improvement within 24–48 hours Uncertain follow-up or barriers to reassessment
Important
Watchful waiting requires active clinical management: prescribe or recommend scheduled weight-based analgesics (acetaminophen 10–15 mg/kg Q4–6H PRN or ibuprofen 10 mg/kg Q6–8H with food PRN) and provide a safety-net prescription or clear instructions to initiate therapy if the child fails to improve or deteriorates within 24 to 48 hours (CPS).
First-Line Antimicrobial Posology: High-Dose Amoxicillin
When antibiotic therapy is indicated, high-dose amoxicillin remains the undisputed first-line agent:
Pediatric Posology (CPS): 75 to 90 mg/kg/day orally divided BID , or 45 to 60 mg/kg/day divided TID . Amoxicillin's half-life is about 1 hour, so twice-daily dosing needs the higher total dose to keep middle-ear levels adequate for over 50% of the day.
Adult Posology: 1,000 mg PO TID (or 875 mg PO BID for mild presentations).
Mechanistic Rationale: Intermediate and high-level penicillin-resistant S. pneumoniae (PRSP) possess altered penicillin-binding proteins (PBP2x, PBP2b). Conventional amoxicillin dosing (40–45 mg/kg/day) yields middle ear fluid concentrations below the minimum inhibitory concentration (MIC), whereas high-dose amoxicillin achieves middle ear concentrations exceeding 2–4 mg/L, maintaining free drug levels above the MIC (T > MIC) for greater than 50% of the dosing interval.
Treatment Duration
Children < 2 years of age, perforated eardrum, recurrent AOM, or failure of initial therapy: 10 full days .
Children ≥ 2 years of age with uncomplicated AOM: 5 days (shorter course decreases selective pressure and diarrhea without compromising clinical cure).
Managing Treatment Failure and High-Risk Features (7:1 Amoxicillin-Clavulanate)
If a child experiences treatment failure (persistent fever, otalgia, or worsening TM bulging after 48–72 hours of high-dose amoxicillin), has received a beta-lactam within the preceding 30 days, or presents with concurrent purulent conjunctivitis (otitis-conjunctivitis syndrome), the likely pathogen is a beta-lactamase-producing strain of H. influenzae or M. catarrhalis .
Second-Line Choice: Amoxicillin-clavulanate, 7:1 formulation (400 mg amoxicillin / 57 mg clavulanate per 5 mL). The CPS notes that a 14:1 formulation is not available in Canada .
Posology (CPS): For a child weighing 35 kg or less, 45 to 60 mg/kg/day of the amoxicillin component divided TID for 10 days . For a child over 35 kg, 500 mg tablets TID for 10 days.
Formulation Science: Clavulanate causes dose-related diarrhea, and more than about 10 mg/kg/day is linked with a higher risk. The 7:1 suspension gives the most amoxicillin with the least clavulanate available in Canada. At 60 mg/kg/day of amoxicillin it delivers about 8.5 mg/kg/day of clavulanate, which stays under that limit. Do not reach a higher amoxicillin dose by increasing a 4:1 or 7:1 product, because this overdoses clavulanate.
If oral therapy fails or cannot be taken: ceftriaxone 50 mg/kg IM (or IV) once daily for 3 days , or referral for tympanocentesis.
Penicillin Allergy Alternatives
Non-Severe (Delayed cutaneous maculopapular rash): Second-generation oral cephalosporins: cefuroxime axetil (30 mg/kg/day divided BID or TID) or cefprozil (30 mg/kg/day divided BID); or ceftriaxone 50 mg/kg IM daily for 3 days.
Severe / IgE-Mediated (Anaphylaxis, bronchospasm, angioedema): Azithromycin (10 mg/kg on Day 1, followed by 5 mg/kg daily on Days 2–5) or Clarithromycin (15 mg/kg/day divided BID). Note that pneumococcal macrolide resistance in Canada exceeds 25%, carrying an increased risk of microbiological failure.
Acute Bacterial Rhinosinusitis (ABRS): Differentiating Viral vs. Bacterial
Acute rhinosinusitis involves inflammation of the mucosal lining of the paranasal sinuses and nasal cavity. Over 98% of episodes originate from viral upper respiratory infections (AVRS). Antimicrobial treatment of viral rhinosinusitis provides zero clinical benefit while exposing patients to adverse reactions. [ Patient with Acute Rhinosinusitis Symptoms ]
│
Does the clinical presentation meet ANY of the 3 bacterial criteria?
- 1. Persistent symptoms >= 10 days without clinical improvement
- 2. Severe onset: Fever >= 39°C + purulent nasal discharge >= 3-4 consecutive days
- 3. "Double sickening": Acute worsening after initial 5-6 day viral recovery
- │
- ┌────────────────┴────────────────┐
- YES NO
- │ │
- [ Acute Bacterial ] [ Acute Viral ]
- [ Rhinosinusitis ] [ Rhinosinusitis ]
- │ │
Initiate Amoxicillin or Symptomatic Relief:
- Amoxicillin-Clavulanate Saline rinse + INCS spray
- (Adults: 5-7 days) (No Antibiotics)
- The Three Validated Clinical Presentations of ABRS
Under Canadian clinical practice guidelines, acute bacterial rhinosinusitis should be diagnosed only when symptoms satisfy at least one of the following patterns:
Persistent Symptoms: Signs and symptoms (purulent anterior/posterior rhinorrhea, nasal obstruction, facial pain/pressure) lasting ≥ 10 calendar days without evidence of clinical improvement.
Severe Onset: Presentation with high fever ( ≥ 39°C ) accompanied by purulent (thick, discolored) nasal discharge and facial pain lasting for at least 3 to 4 consecutive days at illness onset.
"Double Sickening": Classic biphasic pattern where a typical viral upper respiratory infection begins to improve over 5 to 6 days, followed by sudden, acute deterioration marked by new-onset fever, increased headache, facial pressure, or intensified purulent rhinorrhea.
Pharmacotherapy for ABRS
First-Line Uncomplicated Adults: Amoxicillin 500 mg PO TID or 1,000 mg PO TID for 5–7 days.
First-Line with Risk Factors for Resistance: Amoxicillin-clavulanate 875/125 mg PO BID (or 2,000/125 mg extended-release PO BID) for 5–7 days. Risk factors include: age ≥ 65 years, antibiotic exposure within past 30 days, hospitalization within past 5 days, or immunocompromise.
Penicillin Allergy: Doxycycline 100 mg PO BID for 5–7 days OR Respiratory Fluoroquinolones (Levofloxacin 500 mg PO daily or Moxifloxacin 400 mg PO daily).
Adjunctive Therapies: Intranasal saline irrigation and intranasal corticosteroid (INCS) sprays (e.g., mometasone, fluticasone) reduce mucosal inflammation. Topical alpha-agonist decongestants (e.g., xylometazoline 0.1%) provide rapid temporary relief but must be strictly limited to ≤ 3 to 5 consecutive days to prevent rhinitis medicamentosa (rebound mucosal hyperemia and intractable congestion).
Group A Streptococcal (GAS) Pharyngitis & Centor/McIsaac Scoring
Acute pharyngitis is overwhelmingly viral (rhinovirus, adenovirus, coronavirus, Epstein-Barr virus). Streptococcus pyogenes (Group A beta-hemolytic Streptococcus [GAS]) accounts for only 15%–30% of pediatric and 5%–15% of adult sore throats. The primary rationale for antibiotic treatment of GAS pharyngitis is preventing acute rheumatic fever (ARF) , mitigating suppurative complications (e.g., peritonsillar abscess), shortening symptom duration by approximately 24 hours, and preventing transmission.
Modified Centor (McIsaac) Clinical Decision Score
The McIsaac score stratifies the pre-test probability of GAS pharyngitis and guides diagnostic swab testing:
- Clinical Feature Points Assigned
- Absence of cough +1
- Swollen, tender anterior cervical lymph nodes +1
- Tonsillar exudate or tonsillar swelling +1
- History of fever (> 38°C) +1
- Age 3 to 14 years +1
- Age 15 to 44 years 0
- Age ≥ 45 years -1
- Clinical Management Based on Score
Score 0 to 1 (Risk < 10%): No throat swab, no rapid antigen testing, no antibiotic therapy. Provide symptomatic analgesics.
Score 2 to 3 (Risk 15%–32%): Perform throat swab for Rapid Antigen Detection Testing (RADT) or throat culture. Treat with antibiotics only if microbiologically confirmed positive .
Score ≥ 4 (Risk 50%–60%): In Canadian clinical practice, microbiologic confirmation is still recommended prior to initiating antibacterial therapy to curb inappropriate prescribing, though empiric therapy may be initiated pending rapid test results in severely symptomatic individuals.
Note
Antibiotic therapy for GAS pharyngitis initiated within 9 days of symptom onset reliably prevents acute rheumatic fever. Therefore, safely withholding antibiotics for 24 to 48 hours pending throat culture results does not increase the risk of rheumatic complications.
Regimens for Confirmed GAS Pharyngitis
First-Line Drug of Choice: Penicillin V oral :
Children: 250 mg PO BID or TID for 10 days (or 40 mg/kg/day divided BID–TID).
Adolescents/Adults: 300 mg PO TID–QID or 600 mg PO BID for 10 full days .
Alternative First-Line: Amoxicillin 50 mg/kg once daily (max 1,000 mg/day) or 25 mg/kg BID for 10 days. Amoxicillin suspension is widely favored in pediatric practice due to superior palatability.
Penicillin Allergy:
Non-severe allergy (non-IgE): Cephalexin 20 mg/kg/dose BID (max 500 mg BID) for 10 days.
Severe allergy (IgE-mediated anaphylaxis): Clindamycin 20–30 mg/kg/day divided TID (max 300 mg TID) for 10 days, OR Azithromycin 12 mg/kg once daily (max 500 mg) for 5 days.
Community-Acquired Pneumonia (CAP): Triage & Empiric Regimens
Community-Acquired Pneumonia (CAP) involves infection of the pulmonary parenchyma acquired outside of a healthcare facility. Common pathogens include:
Typical Bacteria: Streptococcus pneumoniae (most common bacterial pathogen), Haemophilus influenzae , Moraxella catarrhalis .
Atypical Pathogens: Mycoplasma pneumoniae , Chlamydia pneumoniae , Legionella pneumophila (intracellular organisms that lack peptidoglycan cell walls, rendering beta-lactams completely ineffective).
Viruses: Influenza A/B, Respiratory Syncytial Virus (RSV), SARS-CoV-2.
Inpatient Triage: The CURB-65 Criteria
Clinical triage determines outpatient versus hospital admission based on the validated CURB-65 score (1 point for each):
C — Confusion: New disorientation to person, place, or time.
U — Urea: Blood urea nitrogen > 7 mmol/L (> 19 mg/dL).
R — Respiratory Rate: ≥ 30 breaths/minute.
B — Blood Pressure: Systolic < 90 mmHg OR Diastolic ≤ 60 mmHg.
65 — Age: ≥ 65 years.
- CURB-65 Score 30-Day Mortality Recommended Treatment Setting
- 0 – 1 1.5%–3.0% Outpatient therapy (low mortality risk)
- 2 ~9.0% Inpatient hospital ward or closely supervised outpatient monitoring
- 3 – 5 15%–40% Inpatient hospital admission ; score 4–5 warrants immediate ICU evaluation
- Outpatient Empiric Therapy (CTS / ATS-IDSA Guidelines)
Canadian practice guidelines stratify outpatient CAP based on underlying comorbidity status: [ Outpatient Diagnosis of CAP ]
│
Does the patient have chronic comorbidities or risk factors?
- (COPD, diabetes, CHF, CKD, liver disease, malignancy, asplenia,
- or antibiotic exposure within past 3 months)
- │
- ┌───────────────┴───────────────┐
- NO YES
- │ │
- [ Outpatient WITHOUT Comorbidities ] [ Outpatient WITH Comorbidities ]
- │ │
- Option 1: Amoxicillin Option 1: Beta-lactam Combo
- 1 g PO TID x 5 days Amoxicillin-Clavulanate 875/125 mg BID
- OR PLUS Azithromycin 500 mg Day 1, then
- Option 2: Doxycycline 250 mg daily (or Doxycycline 100 mg BID)
- 100 mg PO BID x 5 days OR
- Option 2: Respiratory Fluoroquinolone
- Levofloxacin 750 mg PO daily OR
- Moxifloxacin 400 mg PO daily x 5 days
Warning
Macrolide Monotherapy Caution: Azithromycin or clarithromycin monotherapy is acceptable only in areas where local S. pneumoniae macrolide resistance is documented to be < 25%. In Canada, widespread pneumococcal macrolide resistance exceeds 25%–35%, making amoxicillin or doxycycline the preferred empiric monotherapy in healthy outpatients.
Note
Ciprofloxacin is NOT a Respiratory Fluoroquinolone: Ciprofloxacin has poor, erratic in vitro activity against Streptococcus pneumoniae . It must never be used for CAP. The designated respiratory fluoroquinolones are levofloxacin and moxifloxacin , which provide potent, reliable pneumococcal and atypical coverage.
Inpatient Non-Severe CAP Regimens
For patients admitted to the hospital ward (CURB-65 score ≥ 2):
Preferred Regimen: IV/Oral Beta-Lactam (Ceftriaxone 1 to 2 g IV daily OR Cefotaxime 1 to 2 g IV Q8H OR Ampicillin-sulbactam 1.5 to 3 g IV Q6H) PLUS Macrolide (Azithromycin 500 mg IV/PO daily) or Doxycycline (100 mg IV/PO BID).
Alternative Monotherapy: Respiratory Fluoroquinolone (Levofloxacin 750 mg IV/PO daily OR Moxifloxacin 400 mg IV/PO daily).
Duration: Standard course is 5 days , provided the patient achieves clinical stability (afebrile for ≥ 48 hours, heart rate < 100 bpm, respiratory rate < 24 bpm, SBP ≥ 90 mmHg, room air SpO2 ≥ 92%, and tolerating oral intake).
Hospital-Acquired (HAP) & Ventilator-Associated Pneumonia (VAP)
Hospital-Acquired Pneumonia (HAP): Pneumonia occurring ≥ 48 hours after hospital admission that was not incubating upon entry.
Ventilator-Associated Pneumonia (VAP): Pneumonia developing ≥ 48 hours after endotracheal intubation and mechanical ventilation.
Microbiology and Resistant Pathogens
Unlike CAP, nosocomial pneumonia involves multidrug-resistant (MDR) pathogens:
Gram-Negative Bacilli: Pseudomonas aeruginosa , Klebsiella pneumoniae , Enterobacter cloacae , Escherichia coli , Acinetobacter baumannii .
Gram-Positive Cocci: Methicillin-Resistant Staphylococcus aureus (MRSA), Methicillin-Susceptible S. aureus (MSSA).
Empiric Regimen Architecture
Empiric therapy must provide high-dose, bactericidal coverage against Pseudomonas aeruginosa and MRSA:
Target Pathogen Antimicrobial Class Specific Agents & Dosages
Pseudomonas aeruginosa Antipseudomonal Beta-Lactam Piperacillin-tazobactam 4.5 g IV Q6H (or extended infusion over 4 hours); Cefepime 2 g IV Q8H; Meropenem 1 g IV Q8H
Pseudomonas (Second Agent) Aminoglycoside or Fluoroquinolone Add Tobramycin (5–7 mg/kg IV daily) or Ciprofloxacin (400 mg IV Q8H) if high risk of mortality or prior IV antibiotics within 90 days.
MRSA Glycopeptide or Oxazolidinone Vancomycin (15–20 mg/kg IV Q8–12H, targeting AUC24/MIC = 400–600); Linezolid (600 mg IV/PO Q12H)
Important
Linezolid vs. Vancomycin in Renal Impairment: Linezolid penetrates epithelial lining fluid (ELF) exceptionally well and carries no nephrotoxic liability. In patients with preexisting acute kidney injury or unstable renal clearance, linezolid is an advantageous alternative to vancomycin. Platelet counts and concurrent serotonergic drugs must be monitored during linezolid courses exceeding 10–14 days.
Clinical Case Vignette: Evaluating Pediatric Otalgia & Treatment Failure
A mother brings her 14-month-old son (weight: 10 kg) to the community pharmacy. The child was diagnosed with acute otitis media 3 days ago at an after-hours walk-in clinic and prescribed amoxicillin 125 mg/5 mL suspension at a dose of 250 mg (10 mL) PO twice daily (50 mg/kg/day). The mother reports the child is still pulling at his right ear, has had little sleep, and developed a fever of 39.2°C this morning.
Pharmacist Clinical Assessment:
Evaluate Current Posology: The prescribed dose of 50 mg/kg/day represents conventional standard dosing, which is inadequate in Canadian practice to overcome intermediate and penicillin-resistant S. pneumoniae . The child received subtherapeutic therapy.
Identify Treatment Failure: The persistence of moderate-to-severe symptoms and fever beyond 48 to 72 hours of amoxicillin confirms clinical treatment failure.
Formulate Recommendation: Because the child failed amoxicillin therapy at 72 hours, the likelihood of beta-lactamase-producing H. influenzae or M. catarrhalis (or resistant S. pneumoniae ) is high. The pharmacist contacts the clinic prescriber to recommend switching to amoxicillin-clavulanate (7:1 formulation), as the CPS advises after amoxicillin failure.
Calculate Posology:
Target amoxicillin dose: 60 mg/kg/day × 10 kg = 600 mg/day = 200 mg PO TID.
Product selection: Amoxicillin-clavulanate 7:1 suspension (400 mg amoxicillin / 57 mg clavulanate per 5 mL = 80 mg/mL amoxicillin).
Dose volume: 200 mg ÷ 80 mg/mL = 2.5 mL PO TID for 10 days (treatment failure, and the child is under 2 years).
Clavulanate check: 600 mg × 57/400 = about 85 mg/day = about 8.5 mg/kg/day, below the 10 mg/kg/day diarrhea threshold.
Patient Counseling: Counsel the mother to administer the medication at the start of a meal to enhance absorption and minimize GI intolerance, schedule acetaminophen or ibuprofen for acute pain control, and follow up if no improvement is noted within 48 hours.